Abbott receives EUA for its rapid COVID-19 antigen self-test BinaxNOW
Category: #health  | By Nikita Chaurasia  | Date: 2021-04-05 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Abbott receives EUA for its rapid COVID-19 antigen self-test BinaxNOW
  • Individuals with or without COVID-19 signs can get BinaxNOW without the need for a prescription.
  • Abbott is reportedly planning to deliver BinaxNOW to major consumer goods retailers.

American multinational medical device company Abbott Laboratories has announced to have received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for BinaxNOW, a self-test antigen for detecting COVID-19.

Individuals with or without COVID-19 signs can get this test without the need for a prescription. In the coming weeks, Abbott is reportedly planning to deliver BinaxNOW to major food, pharmacy, and mass merchandiser retailers. The test will also be available on some of the retailers’ websites.

For those unaware, the BinaxNOW Self-Test, which provides results in just 15 minutes, allows people who have tested positive to isolate themselves immediately, rather than waiting days for lab results or sending away at-home tests.

The test can be used on children as well as all among adults aged 15 and above. Moreover, BinaxNOW will be packaged in a two-count box in order to fulfill serial testing criteria.

Robert B. Ford, President, and CEO at Abbott reportedly stated that when paired with vaccination, the BinaxNOW Self-Test will aid Americans to resume their daily chores.

Initially, Abbott had rolled out the BinaxNOW technical test across the United States and expanded its production across all its manufacturing facilities to 50 million tests every month.

The U.S. Department of Health and Human Services (HHS) had bought the company's first 150 million tests and distributed them to nursing homes, K-12 schools, as well as underserved populations, where they are still in use today and are considered to be a valuable tool in the battle against the Coronavirus.

In similar developments, American manufacturer of diagnostic healthcare products Quidel Corporation has also announced that the FDA has granted its QuickVue® At-Home OTC COVID-19 test an Emergency Use Authorization.

Source Credit –

https://www.benzinga.com/pressreleases/21/03/n20438966/abbotts-binaxnow-rapid-antigen-self-test-receives-fda-emergency-use-authorization-for-asymptomatic

 

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Reliance Jio to release low-cost laptop with 4G capabilities for $184

Reliance Jio to release low-cost laptop with 4G capabilities for $184

By Nikita Chaurasia

Reliance Jio will reportedly release a budget-friendly laptop with an embedded 4G sim card for $184 (around INR 15,000). The company hopes to build on the success of its low-cost JioPhone in India's fiercely competitive market. The Mukesh...

PM Liz Truss to launch comprehensive review of UK’s visa policy

PM Liz Truss to launch comprehensive review of UK’s visa policy

By Nikita Chaurasia

Newly appointed Prime Minister Liz Truss is considering doing a complete review of Britain's visa system, as the nation struggles with severe labor shortages in vital industries. Business leaders across the UK have reportedly praised the decision...

UAE: Entrepreneurs and investors can benefit from visa reforms

UAE: Entrepreneurs and investors can benefit from visa reforms

By Nikita Chaurasia

The visa and business reforms by the UAE will open new prospects for investors, entrepreneurs, IT specialists, job seekers, and tourists, according to credible sources. This will reportedly benefit the region’s economic growth. Business Link...